Concerns regarding the safety of azithromycin in pregnancy - relevance for women with cystic fibrosis.
Azithromycin
Congenital malformations
Macrolide
Pregnancy
Journal
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
ISSN: 1873-5010
Titre abrégé: J Cyst Fibros
Pays: Netherlands
ID NLM: 101128966
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
19
05
2020
revised:
07
08
2020
accepted:
07
08
2020
pubmed:
18
8
2020
medline:
27
1
2022
entrez:
18
8
2020
Statut:
ppublish
Résumé
Chronic oral azithromycin therapy improves clinical outcomes in people with cystic fibrosis (CF), and is recommended for treatment of CF lung disease. Azithromycin is categorized as pregnancy class B. The data for risk of congenital malformations associated with use of azithromycin during pregnancy ranges from no risk to a small increased risk. As with other chronic medications used to treat CF, potential risk to the infant of use of azithromycin during pregnancy must be weighed against the potential risk to the mother of treatment discontinuation. Women with CF considering pregnancy while on chronic azithromycin should be counseled regarding potential risks and benefits.
Identifiants
pubmed: 32800485
pii: S1569-1993(20)30818-3
doi: 10.1016/j.jcf.2020.08.003
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Azithromycin
83905-01-5
Types de publication
Letter
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
395-396Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors report no relevant commercial financial activities related to this work.